Renerve Limited · ASX:RNV
Renerve — Non-Deal Roadshow (September 2025)
28 slides from Renerve's roadshow presentation, Sep 29, 2025
Slide 1: Transforming Nerve Repair Through Science: Sales & Marketing Update
ASX:RNV Sales & Transforming Nerve Repair Marketing Through Science Update ReNerve Board meeting | July 2025 ReNerve Company presentation | September 2025 1
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer Nature of Document: This presentation has been prepared and issued by ReNerve Ltd (Company) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of a
Slide 3: Executive Summary
Executive Summary Development of Novel Nerve Repair & Regeneration Products ReNerve is developing a comprehensive portfolio of products for the nerve repair and regeneration markets and related surgical procedures, with clearly defined commercial demand. Expanding Product Portfolio 4 product ranges
Slide 4: Global Nerve Repair Biomaterial Market
Global Global Nerve Repair Biomaterial Market Global Market by Segment $8.0Bn Nerve Repair 16% $6.0Bn 32% Biomaterial $4.0Bn USD $Bn Market $2.0Bn 52% - Nerve Wrap 2024 2025 2026 2027 2028 2029 2030 2031 Nerve Conduit North America Europe Nerve Grafts USD$1.69Bn ~900k Nerve Compression The Global Ne
Slide 5: ReNerve's Nerve Opportunity
ReNerve’s Nerve Opportunity Nerve Cuff Nerve Conduit Nerve Guide Matrix Bionic Nerve • Used on damaged or transected • Improved Nerve Cuff developed from • An ‘off-the-shelf’, ready to use nerve • An ‘off-the-shelf’, continuous nerve Product nerves with no gaps or gap closure scCO2 tissue, offering
Slide 6: Distribution Network
Distribution Network US Market Expanded Distribution Channels Robust portfolio • Expanded to 21 distributors across the US • Full logistics, warehousing and invoicing in place • Distributors will sell the ReNerve product ranges • Will add additional products as they come to market Focus surgical are
Slide 7: Ex-US Sales & Marketing
Ex-US Sales & Marketing Sales Highlights ReNerve Distribution India has significant potential due to the open market and population with the market valued at USD$115M and growth at 18+%* India a training ground for surgeons India Asia MIDDLE EAST due to number and diversity of cases so good location
Slide 8: Company value drivers for H2 CY25
Continued Market Engagement 3 new products ranges into the US market this CY • Dermal and amniotic products now in market and launched • Have achieved first dermal sale • First conduit product by year end Company value • Provides sales teams a range of four products by year end, expected to aid sale
Slide 9: NervAlign® Nerve Cuff
NervAlian Z Oe Q § pe O 2 Nerve Cuff
Slide 10: Key Features Clinical Use
Key Features Clinical Use Patient Results Product • Majority of cases to date have been focused on hand and • The NervAlign® Nerve Cuff has market clearance in wrist. USA, Hong Kong, Thailand and Bahrain • Shown clinical benefit (published) • The product is used as a barrier between the repaired • A
Slide 11: Clinical Validation
Clinical Validation Clinical Study on the NervAlign® Nerve Cuff Comparison of Patient Pre & Post An independent comparative clinical study was presented at Surgery Pain Score theAmerican College of Foot and Ankle Surgeons Conference (27–30 March 2025), ReNerve presented a comparative clinical study
Slide 12: Clinical Use
Clinical Use NervAlign® Damaged nerve Completed repair Gap filled with a Nerve Cuff used removed from held in place with conduit to protect the cuff the thumb micro clips conduit implant
Slide 13: NervAlign® Conduit
NervAlign® Conduit 02
Slide 14: Key Features
Key Features • ReNerve developing a conduit product range from scCO2 tissue also used in the Nerve Cuff. • ReNerve is leverage existing data from the Nerve Cuff FDA application to accelerate FDA approval. • Offers the followings benefits: • Expands the ReNerve product range and portfolio; • Better r
Slide 15: NervAlign® Nerve Guide Matrix (Graft)
NervAlign® Nerve Guide Matrix (Graft) 03
Slide 16: Key Features & Guide Matrix
Key Features & Guide Matrix Product • The NervAlign® Neve Guide Matrix is an ‘off-the-shelf’, ready to use nerve graft replacement with internal infrastructure. • ReNerve is developing multiple product options: - Initial ‘wet’ prep nerve graft; - Longer lengths out to 7cms+ and various diameters • E
Slide 17: Human Tissue Products
Human Tissue Products 04
Slide 18: ReNerve
ReNerve
Slide 19: Empliq Product Portfolio
Empliq Product Portfolio Empliq AmnioLite Empliq AmnioDuo Empliq Placental Empliq Dermal Single-layer amniotic membrane Double-layer amniotic membrane Placental allograft including amniotic Deep-layer dermal matrix Description allograft allograft membrane and chorion Natural barrier to protect wound
Slide 20: The Berkeley – ReNerve Product Ranges
The Berkeley – ReNerve Product Ranges Expanding the company product range to the same target markets 1| Surgeons using NervAlign 2| They also use dermal and 3| Taking on these products products routinely use dermal amniotic membranes in cases expands ReNerve’s revenue and amniotic membranes in where
Slide 21: Global Dermal & Amniotic Tissue Repair Markets
Dermal & Amniotic Tissue Sales for Specific Surgical Applications in USD$Bn $2,500.00 Global Dermal $2,000.00 & Amniotic $1,500.00 Tissue Repair $1,000.00 Markets $500.00 $0.00 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 Orthopedics (Tendon and Ligament Repair) Surgical Applicat
Slide 22: Benefits of Amniotic Product Range
Benefits of Amniotic Product Range • Used in orthopaedic, plastic and general surgery – especially for chronic wounds and wound closure • Enables rapid, non-pathologic healing and remodelling of surgical and reconstructive wounds • Acts as a natural barrier to protect from external environment • Pro
Slide 23: Deep-Layer Dermal Product Range
Deep-Layer Dermal Product Range • Used in orthopaedic, plastic and general surgery • Provides a scaffold for cell infiltration and organised healing • Scaffold is made from natural bioactive components (collagen, elastin, glycosaminoglycans) • Unlike competitor products, the deep-layer dermal produc
Slide 24: Key Dermal Product Benefits
Key Dermal Product Benefits Unprocessed Dermal Tissue DESIGNED AND PROCESSED TO PRESERVE THE NATURAL MATRIX AS CLOSELY AS POSSIBLE TO UNPROCESSED DERMIS FOR OPTIMAL TISSUE REPAIR AND REGENERATION. CLOSEST TO NATURAL DERMAL TISSUE, COMPARED TO OTHER DERMAL PRODUCTS1. New ReNerve ACHIEVES HIGH STERILI
Slide 25: Near Term Milestones – 2025/2026
Near Term Milestones – 2025/2026 1H 2025 Q4 2025/Q1 2026 Near Term NervAlign® Nerve Conduit into Market 27 February 2025 Nerve Guide Matrix GMP (Q4 2025/Q1 2026) Partnership Signed for Mexico Market production Initial sales of the dermal and 7 March 2025 amniotic product ranges First clinical cases
Slide 26: Investment Highlights
Investment Highlights In Market Products Immediate Market Need Growing Market Nerve Cuff transitioned from R&D to Products promote nerve injury recovery and Nerve repair biomaterials and related markets commercial sales with 3 product lines in wound repair leading to faster patient are forecast to g
Slide 27: Contact
ASX:RNV Contact ReNerve Limited +61 (03) 9482 3940 info@renerve.com.au Level 10/99 Queen St, Melbourne, Victoria 3000 Australia
Slide 28: Board & Management
Board & Management STEPHEN COOPER DR JULIAN CHICK DR MICHAEL PANACCIO DR DAVID RHODES DR ALEX ADAMIDES CHAIRMAN CEO & MANAGING DIRECTOR NON-EXECUTIVE DIRECTOR EXECUTIVE DIRECTOR & CSO CHIEF MEDICAL OFFICER Stephen was previously Managing Dr Julian Chick is an experienced Dr Michael Panaccio is one o